NCT04935138 is a clinical trial of cfDNA analysis in Early Pregnancy Loss, sponsored by Quest Diagnostics-Nichols Insitute.

Who is sponsoring NCT04935138?

NCT04935138 is sponsored by Quest Diagnostics-Nichols Insitute.

What drugs are being tested in NCT04935138?

Interventions in NCT04935138: cfDNA analysis.

What condition does NCT04935138 study?

NCT04935138 studies Early Pregnancy Loss.

Is NCT04935138 still recruiting?

NCT04935138 is currently terminated. Last updated 1 December 2023.

Last reviewed 2023-12-01 · How we verify

NCT04935138

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cell-free DNA Analysis of Chromosome Anomalies in Early Pregnancy Loss

Terminated Last updated 1 December 2023

What this trial tests

trial testing cfDNA analysis in Early Pregnancy Loss in 78 participants. Terminated before completion.

Timeline

1 June 2021

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Quest Diagnostics-Nichols Insitute
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	78
Start date	1 June 2021
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across United States

Drugs / interventions tested

cfDNA analysis

Conditions studied

Early Pregnancy Loss — all drugs for Early Pregnancy Loss →

Sponsor

Quest Diagnostics-Nichols Insitute — full company profile →

Who can join

Adults 18 to 50, female only, with Early Pregnancy Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study assesses the accuracy of cell-free DNA (cfDNA) analysis in detecting whole chromosomal aneuploidies from maternal plasma of patients with early, missed miscarriage.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Cell-Free DNA Analysis of Fetal Aneuploidies in Early Pregnancy Loss.
Kutteh WH, Miller CE, Park JK, Corey V, et al · · 2024 · cited 3× · PMID 39124551 · DOI 10.3390/jcm13154283

Verify or expand the search:

Other recruiting trials for Early Pregnancy Loss

Currently open trials in the same condition.

NCT06647849 — Interest of Simulation Training on the Announcement of Early Pregnancy Loss on the Psychological Impact of the Patients · NA · recruiting
NCT06452719 — Letrozole and Misoprostol for Early Pregnancy Loss Management · Phase 2 · recruiting
NCT05880381 — Virtual Reality for Coping With Involuntary Early Pregnancy Loss · NA · recruiting
NCT04595760 — Factors Influencing Fertility or Pregnancy Health · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04935138 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Quest Diagnostics-Nichols Insitute
Last refreshed: 1 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04935138.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing